Tests a remote arm-cuff treatment in people with ischemic stroke from artery narrowing
Tests a remote cuff treatment on blood flow backups in adults with ischemic stroke.
Plain-language title generated from the registry record
Registry title: Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke
Key facts
- Where
- Shenyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people over 40 who had an ischemic stroke or TIA more than 1 month ago, with a narrowed or blocked large artery in the front of the brain and weak collateral circulation.
- Age
- Over 40 years old
- Sex
- All sexes can join
- Disease stage
- Ischemic stroke (including TIA and cerebral infarction) with onset more than 1 month ago. The large artery of the front brain circulation has atherosclerotic narrowing of 50% or more, or is blocked. Collateral circulation is 0-3 on the ASITN/SIR scale (DSA scan). First stroke, or an earlier one with no significant lasting effects (mRS 2 or less).
- Earlier treatment
- People who are not expected to have angioplasty within 12 months. People who already had a stent, angioplasty or related device on the target blood vessel cannot join.
Main reasons for not taking part
- Severe infection or serious liver, kidney, blood or hormone disease
- Earlier stroke with severe lasting effects (mRS 3 or more)
- Brain bleeding within the last 90 days
- Pregnant or breastfeeding women
- Life expectancy under 1 year
Read by machine on 9 November 2026.
Where in China
- General Hospital of Northern Theater CommandShenyang, ChinaContact: Zi-Ai ZhaoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- General Hospital of Shenyang Military Region
- Trial code
- NCT06170944
- Record updated
- 27 April 2026
- Original description
The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.Read full original descriptionShow less
Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke (RICAS): a Prospective, Randomized, Blind Endpoint, Multicenter Study
The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.
Inclusion: 1. Age over 40 years old; 2. Diagnosed with ischemic stroke (including TIA and cerebral infarction), with onset time of more than 1 month; 3. Culprit arteries are the large arteries of the anterior circulation with atherosclerotic stenosis (≥50%) or occlusion; 4. ASITN/SIR collateral circulation of 0-3 based on DSA evaluation; 5. First onset or prior onset with no significant sequelae (mRS ≤ 2); 6. Those who are not expected to undergo angioplasty within 12 months (judged by the doctor or decided by patients and/or their representatives); 7. The availability of informed consent.
Exclusion: 6) Patients with intracranial hemorrhage (parenchymal hemorrhage, subarachnoid hemorrhage, subdural/epidural hemorrhage) within 90 days before enrollment; 10) Those who are expected to undergo major surgery (including femoral artery, cardiac, aortic or carotid artery surgery) within 30 days before enrollment or within 12 months after enrollment; 11) Those who have received stent implantation, angioplasty or other related medical devices for the target diseased blood vessels, or those who are expected to undergo the above treatments within 12 months after enrollment; 1) Patients with severe infection or serious diseases such as liver, kidney, hematopoietic system, endocrine system, etc; 2) Patients with a history of stroke and severe sequelae (mRS≥3); 3) arterial stenosis due to aortic dissection, moyamoya disease; Any known vasculitic disease; herpes zoster, varicella-zoster or other viral infections with vascular lesions; neurosyphilis; other intracranial infections; any intracranial artery stenosis associated with hypercytosis of cerebrospinal fluid; radiation-induced vascular lesions; myofiber dysplasia; sickle cell disease; neurofibromas; benign vascular lesions of the central nervous system; postpartum vascular disease; stenosis of the intracranial arteries due to vasospasm or thrombosm; 4) Uncontrolled severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110 mmHg after drug treatment) ; 5) Subclavian artery stenosis ≥50% or subclavian artery steal syndrome; 8) Patients with severe hematologic diseases or severe coagulation abnormalities; 9) Retinal hemorrhage or visceral hemorrhage within 30 days; 7) Intracranial tumor, arteriovenous malformation, or aneurysm; 12) Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc; 13) Damage and lesions in the cerebral veins; 14) Pregnant or lactating women; 15) Those who are participating in other clinical trials within 3 months; 16) Life expectancy is less than 1 year; 17) Patients not suitable for this clinical studies considered by researcher.